Source comparison
Melanotan-1 UV Protection Results Timeline: Protocol Comparison
Clinical (0.16mg/kg subcutaneous) 21 days (daily dosing) 5–7 days Day 21–24 2.4× baseline Every 7–10 days Gold standard for photoprotection. Validated in Phase II trials for erythropoietic protoporphyria, dose-response curve well-characterised Research (16mg t
This comparison does not assign a generated winner or score.
- Clinical (0.16mg/kg subcutaneous)
- 21 days (daily dosing)
- 5–7 days
- Day 21–24
- 2.4× baseline
- Every 7–10 days
- Gold standard for photoprotection. Validated in Phase II trials for erythropoietic protoporphyria, dose-response curve well-characterised
- Research (16mg total over 4 weeks)
- 28 days (every other day)
- 6–9 days
- Day 24–28
- 2.0–2.3× baseline
- Every 10–14 days
- Common research dosing. Slightly lower cumulative exposure extends timeline by 3–5 days but reaches comparable endpoint
- Accelerated (0.25mg/kg front-loaded)
- 14 days (daily, then taper)
- 3–5 days
- Day 18–21
- 1.8–2.1× baseline
- Every 5–7 days
- Faster cosmetic results but photoprotective enzymes lag. Peak protection delayed relative to pigment, not recommended without UV discipline
- Low-Dose Conservative (10mg total over 6 weeks)
- 42 days (twice weekly)
- 8–12 days
- Day 35–40
- 1.6–1.9× baseline
- Every 14–21 days
- Slower onset minimises GI side effects and reduces hyperpigmentation risk, but requires patience. Users often abandon protocol before reaching protective threshold